Tesaglitazar
D6160C00047
Phase 3 small_molecule terminated
Quick answer
Tesaglitazar for Type 2 Diabetes is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Type 2 Diabetes
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated